At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 51 enrolled
Drug / intervention
Aripiprazole Lauroxildrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Tolerability of Initiating Aripiprazole Lauroxil in Subjects With Schizophrenia Who Are Inadequately Treated With Paliperidone Palmitate or Risperidone Long Acting Injection
In Brief
A Phase 4 clinical trial evaluating Aripiprazole Lauroxil for Schizophrenia. Completed, enrolled 51 participants across 18 sites.
Detailed Summary
This study will evaluate the safety and tolerability of aripiprazole lauroxil (also known as ARISTADA, ALKS 9070).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartDec 2015
First PostedDec 2015
Primary CompletionJul 2017
TodayJul 2026
First PostedDec 18, 2015
Enrollment StartDec 1, 2015
Primary CompletionJul 11, 2017
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 10.5 years ago
Interventions
Aripiprazole Lauroxildrug
Monthly IM injection